For Healthcare Professionals

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

clipboard-pencil

About the study

This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
  2. Life expectancy >/= 12 weeks
  3. Adequate hematologic and end-organ function
  4. For participants receiving therapeutic anticoagulation: stable anticoagulant regimen
  5. Negative serum pregnancy test for women of childbearing potential
  6. Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy
  7. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  8. Availability of representative tumor specimens Key General

EXCLUSION CRITERIA

  1. Pregnant or breastfeeding, or intending to become pregnant during the study
  2. Significant cardiovascular disease
  3. Current treatment with medications that prolong the QT interval
  4. Known clinically significant liver disease
  5. Poorly controlled Type 2 diabetes mellitus
  6. Symptomatic, untreated, or actively progressing CNS metastases
  7. History of leptomeningeal disease
  8. History of malignancy other than disease under study within 3 years prior to screening
  9. Active or history of autoimmune disease or immune deficiency
  10. Active tuberculosis, hepatitis B, hepatitis C, or known/suspected Epstein Barr virus infection
  11. Positive for HIV infection
  12. Prior allogeneic stem cell or solid organ transplantation
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 888-662-6728Email iconEmail Study Center

Study’s details


Contition

Solid Tumors

Age (in years)

18 - 200

Phase

Phase 1

Participants needed

250

Est. Completion Date

Jun 2024

Treatment type

Interventional


Sponsor

Genentech, Inc.

ClinicalTrials.gov identifier

NCT04250155

Study number

GO41596

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.